Abbott Laboratories (ABL.DE)
| Previous Close | 112.22 |
| Open | 112.32 |
| Bid | 113.54 x 69000 |
| Ask | 113.76 x 78000 |
| Day's Range | 111.66 - 113.70 |
| 52 Week Range | 90.00 - 114.14 |
| Volume | |
| Avg. Volume | 570 |
| Market Cap | 197.758B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 36.03 |
| EPS (TTM) | 3.15 |
| Earnings Date | Jan 22, 2025 - Jan 27, 2025 |
| Forward Dividend & Yield | 2.09 (1.86%) |
| Ex-Dividend Date | Oct 15, 2024 |
| 1y Target Est | N/A |
GlobeNewswireInspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta
PR NewswireAbbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis
Abbott (NYSE: ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical developm
